purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation nvcr earnings call period ending december image source motley fool novocure nvcr q earnings callfeb etcontents prepared remark question answer call participant prepared remark operatorgood day thank standing welcome novocure q earnings conference call time participant listenonly mode speaker presentation questionandanswer session operator instruction please advised today conference recorded would like hand conference speaker today ingrid goldberg please go aheadingrid goldberg vice president finance investor relation good morning thank joining u review novocures fourth quarter performance joined morning executive chairman bill doyle ceo asaf danziger cfo ashley cordova member executive leadership team available qa reference slide accompanying earnings release found website wwwnovocurecom investor relation page quarterly report start would like remind discussion conference call include forwardlooking statement actual result could differ materially projected statement statement involve number risk uncertainty beyond control described time time sec filing intend update publicly forwardlooking statement except required law appropriate refer nongaap financial measure evaluate business specifically adjusted ebitda measure earnings interest tax depreciation amortization sharebased compensationwe believe adjusted ebitda important metric remove impact earnings attributable capital structure tax rate immaterial noncash item best reflects financial value generated business reconciliation nongaap gaap financial measure included press release earnings slide form k filed sec today material also accessed investor relation page website following prepared remark today open line question turn call executive chairman bill doyle bill doyle executive chairman thank ingrid novocure mission extend survival aggressive form cancer development commercialization novel therapy tumor treating field made notable stride reached many important milestone commercial clinical research product development program commercial business treating patient gbm finished year yearoveryear growth active patient therapy lunar phase trial nonsmall cell lung cancer met primary endpoint completed enrollment two additional phase trial metis panova completed enrollment trident trial january launched lunar panova initiating site enrolling patient protocol two new clinical trial keynote lunar regulatory review successfully introduced nextgeneration array several european country filed pma supplement approval bring new array patient yous importantly treated patient since first started commercial operation ended year record number active patient therapy incredibly proud colleague achievement look forward data catalystsdriven important year novocure milestone horizon laserfocused achieving three core objective growing gbm business launching ttfields nonsmall cell lung cancer delivering clinical product development pipeline achieving objective position company success year come begin morning review commercial gbm business nonsmall cell lung cancer program asaf provide clinical trial product development update followed ashleys review financial performance commercial gbm business key longterm success driving growth core country market central objective ended record active patient tumor treating field therapy generated million net revenue year achieve growth goal focused building greater awareness engagement patient prescribers enhancing quality engagement focused seamless crossfunctional alignment synchronized approach driving key lever growth prescription patient start compliance therapy duration input critical best outcome patient achieving sustainable growth always datadriven organization healthcare provider move integrate ttfields therapy practice determined provide clinical data best inform ttfields therapy use critical part effort generation realworld evidence last month jp morgan shared preliminary analysis realworld study included newly diagnosed gbm patient began optune gio treatment yous second half fouryear survival rate patient compared patient treated chemotherapy alone historically worth noting realworld data fully support result landmark ef phase clinical trial demonstrated fouryear survival patient treated ttfields temozolomide new realworld data added peerreviewed published later year bottom line large realworld datasets confirm tumor treating field therapy provide significant survival benefit patient struggling devastating disease continue generate realworld data working increase physician awareness outcome importantly build patient awareness data therapy unique modality know physician patient drive choice ttfields therapy option end adjusted organization integrate patient support physician support earlier patient journey direct engagement physician enable team provide handson assistance time prescription considered written believe early engagement patient drive higher conversion script patient start deliver seamless therapy experience second key objective regulatory approval successful launch tumor treating field nonsmall cell lung cancer reminder last year published result phase lunar trial lunar showed statistically significant clinically meaningful survival benefit secondline nonsmall cell lung cancer patient progressed platinumbased chemotherapy used ttfields standard therapy compared patient used standard therapy since announcing positive topline lunar data made steady progress toward goal commercial launch december filed necessary regulatory submission three major market yous europe japan january fda formally accepted pma submission filing pma substantive review day mark occur midmarch anticipate meeting fda discus next step team fully prepared address question look forward engaging fda coming month outside yous awaiting ce mark decision europe regulatory next step japan pending regulatory approval goal launch germany first half yous second half receive marketing approval engage payer germany yous establish reimbursement plan start patient therapy germany yous immediately following approval using namedpatient reimbursement process similar used launched gbm eager open new chapter novocure look forward potentially treating many patient coming month team also deliver topline result metis panova clinical trial trial fully enrolled patient followup asaf discus trial momentarily timing indicates novocure could announce material data new indication approval every quarter going exciting year pas call asaf discus clinical program would like publicly welcome new chief medical officer dr nicolas leupin joined novocure january dr leupin brings wealth valuable experience novocure former practicing oncologist leader clinical operation innovative biotechnology company nicolas proven track record achievement making great contribution already nicolas michael puri new chief human resource officer joined q important addition executive team welcome michael welcome nicolas turn call asaf discus clinical objectivesasaf danziger chief executive officer thank bill mentioned focused three objective grow gbm business launch lung cancer deliver pipeline consolidated clinical trial initiative three indication proven efficacy address significant unmet need gbm nonsmall cell lung cancer pancreatic cancer optune gio together temozolomide nccn category preferred therapy regimen newly diagnosed gbm considered standard care believe extend survival even two phase trial focused goal first trident completed enrollment last month trident studying survival benefit starting optune gio chemoradiation rather chemoradiation two three month earlier today standard protocol clinical study preclinical research shown mechanism action radiation ttfields work together create pronounced cytotoxic environment cancer cell potentially extend patient survival trident month followup last patient topline result available addition trident submitted ind fda preparing launch phase keynote trial keynote study optune giotemozolomide immunotherapy pembrolizumab treatment newly diagnosed gbm keynote initiated confirm preclinical research exciting clinical data dr david trans thetop phase trial sno annual meeting november dr tran presented updated data thetop median overall survival patient trial month compared month match control cohort ef dataset thetop phase result promising eager launch keynote begin enrolling patient year trident keynote technological improvement like new array provide possibility improve survival gbm patient demonstrate continued commitment neurooncology field look forward sharing information program future also focused treatment nonsmall cell lung cancer success lunar trial provides foundation number additional lung cancer trial last year ide approved lunar began site initiation lunar evaluate use ttfields together immunotherapy pembrolizumab platinumbased chemotherapy firstline metastatic nonsmall cell lung cancer protocol phase lunar trial review regulatory authority hope launch later year lunar study use ttfields immunotherapy second line following firstline immunotherapy also continue enroll patient phase keynote b trial evaluating ttfields therapy pembrolizumab firstline treatment locally advanced metastatic nonsmall cell lung cancer given success lunar believe scratching surface potential ttfields nonsmall cell lung cancer also exploring use ttfields treatment secondary tumor phase metis trial starting ttfields following stereotactic radiosurgery brain metastasis nonsmall cell lung cancer finished enrolling metis march complete minimum month followup last patient coming week followup complete expect announce topline result end q metis address significant unmet need large heterogeneous patient population eager understand ttfields provide benefit patient aggregate nonsmall cell lung cancer program include five trial lunar lunar lunar keynote b metis trial allow u study use ttfields across multiple stage nonsmall cell lung cancer potential unlock availability ttfields therapy ten thousand patient third clinical program focused pancreatic cancer two ongoing clinical trial pancreatic cancer panova panova phase panova trial evaluating use ttfields together nabpaclitaxel gemcitabine treatment firstline locally advanced pancreatic cancer completed enrollment panova last year expect announce topline result q also launched phase panova trial last year panova evaluating addition immunotherapy atezolizumab regimen used panova treat firstline metastatic pancreatic cancer unfortunately pancreatic cancer indication growing great unmet need look forward reviewing data trial soon possible previously mentioned also exploring opportunity improve therapy product development launched nextgeneration array europe gbm feedback positive patient mentioned increased comfort ease use december filed pma supplement approval market new array yous approved look forward launching yous patient second half extremely encouraged achievement excited catalyst horizon year team focused key objective energized reach patient need look forward updating progress throughout year ashley run fourth quarter full year performanceashley cordova chief financial officer thank asaf fourth quarter another quarter progress execution novocure setting stage strong generated million net revenue quarter million year ended year record active patient therapy increase yearend one key objective year drive growth gbm business transition several complex situation affected business recent year largely resolved includes depletion accessible flow backlogged medicare payment achievement revenue baseline newly launched french market successful negotiation german payer resolution variable serf strengthen foundation net revenue growth year directly tied active patient therapy duration therapy price novocures team every function aligned support enhance driver beyond one victory fourth quarter continued success optune gio launch france business france tailwind emea active patient count throughout year contributed million fourth quarter set strong baseline move fourth quarter also saw strength germany yearoveryear increase prescription active patient therapy reminder mid engaged german payer negotiate updated contract term effectively paused german business expected took approximately six quarter recover moving forward expect fourth quarter serve baseline german market gross margin fourth quarter color gross margin affected two nearterm factor investment increased patient support capacity rollout nextgeneration array time expect factor offset increased active patient count improved efficiency scale optimize manufacturing new array last year implemented portfolio prioritization strategic restructuring initiative realign business support nearterm growth longterm value creation result initiative streamlined operating expense removing million residual opex streamlining enable u invest future growth initiative like nonsmall cell lung cancer launch without increasing cash burn believe immense potential tumor treating field platform investing accordingly also recognize need accelerate path profitability confident recent adjustment position novocure create shareholder value achieving mission extending survival aggressive form cancer sga expense fourth quarter million looking ahead sga expenditure would distributed support area highest growth potential alignment goal includes global commercial infrastructure launch preparation ahead anticipated nonsmall cell lung cancer launch research development clinical trial cost quarter million rd spending largely tied number ongoing clinical trial given moment current slate phase trial nears conclusion process launching next set trial including lunar keynote following portfolio prioritization effort last year future rd investment focused area highest return gbm nonsmall cell lung cancer pancreatic cancer cash shortterm investment totaled million december net loss fourth quarter million per share adjusted ebitda negative million prepare potential treat thousand additional patient year come committed ensuring incremental investment allocated area align longterm strategic vision goal focus growth investment area highest potential return maintaining balance sheet strength accelerating path profitability would like close today highlighting one optune gio patient janice armbrust los angeles janice moved new york city met jeff love life avid nature enthusiast janice jeff soon scaling mountain across country together janice diagnosed gbm began treatment optune gio amid fear uncertainty gbm diagnosis janice jeff decided pursue passion married moved california better enjoy outdoor lifestyle optune gio janices shoulder janice jeff continued scale mountain plan hike rock climb across globe people like janice constant reminder impact make patient life helping reach birthday anniversary summit new mountain hand call back operator question question answer operatorthank operator instruction first question come jason bednar piper sandlerjason bednar piper sandler analyst hey good morning thanks taking question hear rightashley cordova chief financial officer canjason bednar piper sandler analyst excellent bill ashley wanted first start upcoming metis readout wanted confirm see typical headline release data next month venue planning present full result see fact metis using ttfields monotherapy advantage disadvantage trial anything read fact brain mets one three area consolidated clinical research activitiesbill doyle executive chairman sure good morning jason correctly underlined eagerly awaiting data announcing topline result end quarter yet announced venue full data presentation get cleaned know applying slot would audio gap season conference fall season late spring season respect core focus area consider part lung program metis studying brain metastasis nonsmall cell lung cancer common form brain mets well within core staked gbm nonsmall cell lung cancer pancreatic cancerashley cordova chief financial officer thing would add yes expect standard press release u similar handled topline data release releasejason bednar piper sandler analyst ok great sorry background noise try ask next one quick wanted ask duration wear think looking lot way keep patient therapy longer revenue implication could pretty meaningful trident trial starting patient earlier rather waiting radiotherapy complete think talked educating doctor patient survival benefit wearing optune longer throughout day got new array supposed clinical benefit sort looking potentially keeping patient longer even progression individually interesting guess collectively could pretty impactful know trident coming couple year could actually see benefit item extend duration wear impact revenue soonerfrank leonard president yous central nervous system cancer hi jason frank leonard thank question think know thank highlighting activity ongoing area really focused improving patient physician use optune extend survival think would know point directly new array released key european market tracking looking wide array kpis ass performance seen far metric well anecdote performance meeting expectation looking positive trend patient experience think collectively lot opportunity move needle continue update metric come injason bednar piper sandler analyst ok fair enough maybe one ashley know one point formal level financial guidance stepped away couple different reason seems like business back predictable willing comment offer kind like forwardlooking outlook whether year high level thinking next year think growth business thank youashley cordova chief financial officer thanks jason appreciate question mean always committed providing necessary color guy look ahead would say feel like need provide detailed color heard message focused know return growth gbm business believe clean baseline major market upon build growth right audio gap germany yous largely look good baseline upon model activation growth restructuring announcement q last year heard u directly state think run business residual opex know fully support lung launch look opex run rate would expect u able invest infrastructure need launch lung run rate running q q think kind anchor message need build model would say continue flag feel additional area need adjustjason bednar piper sandler analyst ok thanks muchoperatorthank one moment next question next question come jonathan chang leerink partnersjonathan chang leerink partner analyst hi guy thanks taking question first question ahead potential lung cancer approval launch talk prelaunch activity planned ongoing thinking initial launch trajectory could look like second question following portfolio prioritization strategic restructuring last year thinking cash position balance sheet ahead two phase readout coming year study positive wellpositioned advance opportunity thank youfrank leonard president yous central nervous system cancer thank question jonathan frank leonard audio gap united state focus education really direct engagement potential prescribers advisory board process one main area focus simply work physician understand acknowledge gap secondline treatment nonsmall cell lung cancer seen heard clearly physician satisfied option treatment platinum failure think aligning working physician align core mutual understanding first step begin educate introduce tumor treating field acknowledge medical oncology community new modality go education process help understand audio gap really pleased today term engaging key kols preparing plan yous pull would also note germany also prelaunch phase waiting ce mark able engage germany key physician prelaunch activity nonsmall cell lung cancer also launch optune lua mesothelioma audio gap engaged community germany help education curve ultimately prepare market launchashley cordova chief financial officer mean one thing jonathan would flag medtech launch curve look model everybody building would look gbm launch curve stereotypical biotech curve particular come reimbursement dynamicsbill doyle executive chairman yeah think question asked respect cash position preparation launch prepared part strategic plan fully finance nonsmall cell lung cancer launch budget anticipate metis readout overlap key prescriber group recall metis treating patient stereotactic radiosurgery radiation oncologist engage gbm business radiation oncologist principally treating patient along primary medical oncologist treating nonsmall cell lung cancer believe cash perspective wellcovered nonsmall cell lung cancer launch potential launch pending outcome metisjonathan chang leerink partner analyst understood thanks taking questionsoperatorthank one moment next question next question come larry biegelsen well fargolei huang well fargo security analyst hi good morning lei calling larry hear okashley cordova chief financial officer leilei huang well fargo security analyst thanks taking question first one actually guy provide guidance give color think using base give detail far think pace active patient growth think relatively know balanced growth sort acceleration think related expect prescription growth well gbm contribution lung look followupashley cordova chief financial officer yeah thanks lei mean reiterate said said earlier think clean baseline upon know grow lever growth fundamentally active patient growth come prescription growth come better conversion script start come increasing duration focused lever know transparently going able give additional detail expect say know expect see growth incentivizing team grow everything grow geography think look france room know continue grow strong q think done seeing kind mature france market look like would say yes clean baseline yes looking ahead growthlei huang well fargo security analyst got anything lung far contribution ashley cordova chief financial officer yeah one would guide conservative model would expect material revenue contribution reimbursement dynamic begin namedpatient basis take couple quarter get first appeal cycle leading indicator adoption first prescription active patient really revenue begin materially accrete lei huang well fargo security analyst got ok thanks followup know announced reorg plan recently talked keeping expense kind check reach breakeven point math get something around million total revenue order reach breakeven point right little million total revenue talk know thinking right way far million mark color provide timing pathway driver obviously gbm growth lung know additional color would get thanksashley cordova chief financial officer say lei summarized well would say know track thinking would agree done work make sure able scale growth existing operating expense includes know look run rate exiting q hiring lung course know residual know cash removed business back half year last year able fund growth correct path profitability driven scale topline growth number would say summarized welloperatorthank one moment next question next question come emily bodnar hc wainwrightemily bodnar hc wainwright company analyst hi good morning thanks taking question could clarify expecting ce mark secondline lung europe soon would think would ready launch assuming receive europe approval kind increase confidence fda approval thanksasaf danziger chief executive officer thank question asaf submitted material notified body europe last july expecting approval first half year questionashley cordova chief financial officer inaudible fdaasaf danziger chief executive officer fda submitted package pma last december know received confirmation filed looking looking forward next step day meeting expect end marchemily bodnar hc wainwright company analyst ok soon approval europe would ready launchbill doyle executive chairman ready launch approvalemily bodnar hc wainwright company analyst ok thank youoperatorthank one moment final question come vijay kumar evercore isiunknown speaker good morning kevin long vijay one opex level noted million initiative term opex saving inclusive year expect opex grow line revenue see stepup given number clinical trial follow expecting free cash flow thank youashley cordova chief financial officer yeah million intentional enable fully able invest nearterm growth longterm priority also happy coincidence sufficient fund lung launch onboarding large phase trial expect really ramp year principally lunar keynote expect opex level full year largely line full year given restructuring would say statement cash burnunknown speaker got thank lunar program noted meeting fda midmarch expect put press release let street know communication fda would provide update marchashley cordova chief financial officer yeah mean make sure material relevant information press release would tie fda formal public announcement would sayunknown speaker got thank youoperatorthank would like turn back bill doyle closing remarksbill doyle executive chairman would like start closing remark reiterating thanks novocure team hard work many milestone achieved company bigger complex team dedication mission help patient difficult diagnosis something proud exciting looking forward even exciting discussed three fully enrolled phase trial read year one follow rolling nextgeneration array throughout europe really excited audio gap get pma supplement approval year going launch nonsmall cell lung cancer next big indication extremely busy time extremely exciting want thank everyone call today continued interest novocure look forward reporting result activity year progressesoperatoroperator signoff duration minutescall participantsingrid goldberg vice president finance investor relationsbill doyle executive chairmanasaf danziger chief executive officerashley cordova chief financial officerjason bednar piper sandler analystfrank leonard president yous central nervous system cancersjonathan chang leerink partner analystlei huang well fargo security analystemily bodnar hc wainwright company analystunknown speaker nvcr analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool position recommends novocure motley fool disclosure policy